Potential of buprenorphine/naltrexone in treating polydrug addiction and co-occurring psychiatric disorders
Potential of buprenorphine/naltrexone in treating polydrug addiction and co-occurring psychiatric disorders
复制标题
DOI：
10.1038/sj.clpt.6100503
复制
发表时间：
2008-04-01
影响因子：
6.7
通讯作者：
McCann, D. J.
中科院分区：
文献类型：
--
作者：
McCann, D. J.
近年来，我们看到监管部门批准了几种治疗药物成瘾症的新药物疗法。在美国，最值得注意的发展是丁丙诺啡被批准用于治疗阿片类药物依赖，其在办公室环境中的处方供应导致数千名额外的患者接受治疗。虽然仍然缺乏经批准的治疗可卡因和甲基苯丙胺依赖的药物，但国家药物滥用研究所为满足这些临床需求做出了大量努力。(1)最近关于莫达非尼治疗可卡因依赖的研究特别令人鼓舞。展望未来，迫在眉睫的挑战是多种药物成瘾，这种情况往往因同时发生的精神疾病而复杂化。当我们努力满足这些复杂患者的需求时，丁丙诺啡/纳洛酮的研究可能是取得重大进展的关键。
In recent years, we have seen regulatory approval being given for several new pharmacotherapies in the treatment of drug addiction disorders. Within the United States, the most noteworthy development has been the approval of buprenorphine in the treatment of opioid dependence, and its availability for prescribing in an office-based setting has resulted in thousands of additional patients going into treatment. Although approved medications for the treatment of cocaine and methamphetamine dependence are still lacking, the National Institute on Drug Abuse has devoted substantial effort toward meeting these clinical needs.(1) Recent studies of modafinil for the treatment of cocaine dependence have been especially encouraging. Looking to the future, the looming challenge is polydrug addiction, a situation that is often complicated by co-occurring psychiatric disorders. As we strive to address the needs of these complicated patients, studies of buprenorphine/naltrexone may hold the key to a major advance.